Novo Nordisk announced on February 24 that it would reduce the list prices of Wegovy and Ozempic in the United States by up to 50%—the largest price reduction in the company's history and a direct response to mounting political, competitive, and regulatory pressure.
The New Pricing Landscape
With these cuts, the GLP-1 pricing landscape has shifted dramatically in 18 months:
- Wegovy (semaglutide): ~$675/month (down from $1,349)
- Ozempic (semaglutide, diabetes): ~$450/month (down from $935)
- Zepbound (tirzepatide): ~$550/month (Eli Lilly held pricing)
- Foundayo (orforglipron, oral): $149/month (new entrant)
- Medicare negotiated rate: $274/month (effective Jan 2027)
What Drove the Cuts
Three converging forces made price reductions inevitable. First, the Inflation Reduction Act gave Medicare negotiating power, establishing a $274/month benchmark. Second, Eli Lilly's $149 oral option applied downward pressure. Third, bipartisan Congressional scrutiny of GLP-1 pricing had reached fever pitch.
Physician-Led GLP-1 Programs From $99/mo
Board-certified doctors. Quarterly labs. Supplement protocols. A real discontinuation plan from day one.
Get Started →Patient Access Implications
Lower list prices improve the economics for uninsured and underinsured patients who pay out of pocket. They also reduce the cost basis for employer health plans, which may now cover GLP-1s more broadly. However, pharmacy benefit managers (PBMs) may adjust rebate structures, meaning the net price impact varies by payer.
The most significant access expansion comes from Medicare. An estimated 7 million Medicare-eligible seniors with obesity will gain coverage in 2027, representing the largest expansion of obesity pharmacotherapy in U.S. history.
Price is no longer the primary barrier to GLP-1 access. The new barrier is quality of care. With medications more affordable, the question shifts from "can I get it?" to "am I getting the right protocol around it?" That distinction will define outcomes for the next generation of patients.